))
23: Clinical Applications of Biomarkers and Large-Scale Collaborative Research with Charles Adler
Manage episode 458683921 series 3632859
Контент предоставлен The Michael J. Fox Foundation for Parkinson’s Research. Весь контент подкастов, включая эпизоды, графику и описания подкастов, загружается и предоставляется непосредственно компанией The Michael J. Fox Foundation for Parkinson’s Research или ее партнером по платформе подкастов. Если вы считаете, что кто-то использует вашу работу, защищенную авторским правом, без вашего разрешения, вы можете выполнить процедуру, описанную здесь https://ru.player.fm/legal.
Substantial research has focused on identifying biomarkers for the diagnosis of Parkinson's disease (PD) as well as monitoring progression of the disease. In developing these biomarkers, it is critical for scientists to consider how the biomarkers will ultimately be used in the clinic and in clinical trials research. In this interview, Dr. Charles (Chuck) Adler shares his perspectives on how biomarkers are currently being used in clinical and research contexts, and what it would take for him to use them more often in clinical practice. He also discusses how groundbreaking collaborative research studies, including the Arizona Study of Aging and Neurodegenerative Disorders and the Parkinson's Progression Markers Initiative (PPMI), are having major impacts on the field. Chuck is Consultant and Professor of Neurology in the Department of Neurology and The Wayne and Kathryn Preisel Professor of Neuroscience Research at the Mayo Clinic Alix School of Medicine at the Mayo Clinic in Arizona.
This podcast is geared toward researchers and clinicians. If you live with Parkinson’s or have a friend or family member with PD, listen to The Michael J. Fox Foundation Parkinson’s Podcast. Hear from scientists, doctors and people with Parkinson's on different aspects of life with the disease as well as research toward treatment breakthroughs at https://www.michaeljfox.org/podcasts.
32 эпизодов
Поделиться
